Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Fuad Bashjawish

Fuad Bashjawish

Cape Fear Valley Hospital, USA

Title: Rare case of primary retroperitoneal dedifferentiated liposarcoma

Biography

Biography: Fuad Bashjawish

Abstract

Introduction:Retroperitoneal sarcomas are extremely rare tumors only affecting 2 to 5 people per million population, which accounts for 0.1% of all malignancies. The most important prognostic factors are tumor grade, the presence of positive margins, tumor integrity, and degree of resection.

Purpose: Our purpose is to make the medical community aware of the medical and surgical treatment of a rare and insidious form of cancer to improve the prognosis of these patients.

Case presentation: The patient is a 73yo male who presented to our institution with a large abdominal mass. On workup, a CT abdomen/pelvis demonstrated a 15x15cm heterogeneous, left-sided intra-abdominal mass extending from the inguinal region superiorly to the level of the kidney. The patient underwent radical resection of the retroperitoneal tumor, left colectomy and left nephrectomy. Final pathology demonstrated a high grade, dedifferentiated liposarcoma with the rhabdomyosarcomatous component. The postoperative course is complicated with a small intraabdominal abscess formation diagnosed on imaging as well as a residual tumor in the left abdomen. The abscess was treated with IV antibiotics and the patient was discharged home. The patient was then re-admitted for fascial dehiscence and was taken back to the operating room for an additional resection of a retroperitoneal mass and Hartmann's procedure.

Conclusion: Achieving a complete resection and the grade of the tumor are the most important prognostic factors for a patient’s survival. Further research into different treatment methods with systemic chemotherapy or novel targeted therapeutic trials may improve the outcomes of these patients.